Spin-offs

AELIX Therapeutics, SL based in Barcelona, is a spin-off of the HIVACAT vaccine research consortium. The company focuses on the discovery and development of immunotherapies against HIV infection. A first round of funding (11.5 million euros) was closed in January 2016. A phase II proof-of-concept clinical trial using the HTI immunogen as a therapeutic vaccine in people with HIV infection is foreseen to be completed by 2020. 

AlbaJuna Therapeutics is the result of the agreement between IrsiCaixa, Grifols corporation and the researchers Bonaventura Clotet, Jorge Carrillo and Julià Blanco. The spin-off is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the “natural killer” cells responsible for destroying cells infected by the virus.